MedTrace Logo

Midodrine for the Early Liberation of Vasopressor Support in the ICU (LIBERATE Multi-Site)

NCT05058612 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 870

Last updated 2026-01-20

No results posted yet for this study

Summary

Vasopressors are medications that are given intravenously to increase the blood pressure of patients with illnesses that cause dangerous blood pressure drops. When a doctor prescribes a vasopressor, they ask that the dose be adjusted to achieve a specific blood pressure. This kind of medical support with intravenous (IV) vasopressors are usual treatments in intensive care unit (ICU) settings. Oral vasopressors, such as midodrine, have been historically used to maintain blood pressure in non-critically ill patients. In this study, the investigators will be using midodrine to reduce the need for IV vasopressors as blood pressure improves during the stay in the ICU.

This LIBERATE multi-site study will continue the work of the LIBERATE feasibility RCT study to evaluate the role of midodrine for patients with low blood pressure in the ICU. It is comprised of the multi centre pilot RCT followed by the definitive multi centre RCT.

Conditions

  • Vasoplegia

Interventions

DRUG

Midodrine

10 mg PO/NG q8h

DRUG

Placebo

Microcrystalline cellulose PO/NG 18h

Sponsors & Collaborators

  • University Hospital Foundation

    collaborator OTHER

  • Institute of Health Economics, Canada

    collaborator OTHER

  • Alberta Health services

    collaborator OTHER

  • University of Alberta

    lead OTHER

Principal Investigators

  • Oleksa Rewa, MD · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-22
Primary Completion
2027-03-31
Completion
2028-02-29

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05058612 on ClinicalTrials.gov